DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Pixantrone is an investigational drug.
There have been 18 clinical trials for Pixantrone. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2004.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Lymphoma, B-Cell. The leading clinical trial sponsors are CTI BioPharma, Theradex, and Johannes Gutenberg University Mainz.
Recent Clinical Trials for Pixantrone
|Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma||The Lymphoma Academic Research Organisation||Phase 2|
|Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer||CTI BioPharma||Phase 1|
|Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study||University of Aarhus||Phase 1/Phase 2|